PRESS RELEASE
Ampersand Announces Successful Exit of CutisPharma
Wellesley, Mass., March 26, 2018. Ampersand Capital Partners announced today that portfolio company CutisPharma has been acquired by NovaQuest Capital Management, LLC. In December 2014, Ampersand completed a growth equity investment into CutisPharma, which at the time was a founder-run company with no institutional investors. Ampersand’s goal was to actively support management in the building of CutisPharma’s operational capabilities and the development FDA approved products. In January 2018, Cutis announced the approval of FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of lostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.
Eric Lev, Partner at Ampersand Capital noted, "CutisPharma has undergone an amazing transformation over the last three years; we're very pleased to have been a partner to CEO Neal Muni and his management team in building Cutis into a fully integrated specialty pharmaceutical company.”
Eric Lev, Partner at Ampersand Capital noted, "CutisPharma has undergone an amazing transformation over the last three years; we're very pleased to have been a partner to CEO Neal Muni and his management team in building Cutis into a fully integrated specialty pharmaceutical company.”